25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

QNCX (Quince Therapeutics, Inc.) Stock Analysis
Buy, Hold or Sell?

Let's analyze Quince Therapeutics, Inc. together

I guess you are interested in Quince Therapeutics, Inc.. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • 📊 Fundamental Analysis (FA) – Quince Therapeutics, Inc.’s Financial Insights
  • 📈 Technical Analysis (TA) – Quince Therapeutics, Inc.’s Price Targets

I'm going to help you getting a better view of Quince Therapeutics, Inc.. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Quince Therapeutics, Inc.

I send you an email if I find something interesting about Quince Therapeutics, Inc..

1. Quick Overview

1.1. Quick analysis of Quince Therapeutics, Inc. (30 sec.)










1.2. What can you expect buying and holding a share of Quince Therapeutics, Inc.? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
4.0%

What is your share worth?

Current worth
$0.70
Expected worth in 1 year
$-0.57
How sure are you?
20.0%

+ What do you gain per year?

Total Gains per Share
$-1.27
Return On Investment
-125.7%

For what price can you sell your share?

Current Price per Share
$1.01
Expected price per share
$0.9195 - $1.3
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Quince Therapeutics, Inc. (5 min.)




Live pricePrice per Share (EOD)
$1.01
Intrinsic Value Per Share
$1.18 - $1.78
Total Value Per Share
$1.88 - $2.48

2.2. Growth of Quince Therapeutics, Inc. (5 min.)




Is Quince Therapeutics, Inc. growing?

Current yearPrevious yearGrowGrow %
How rich?$30.1m$86.3m-$37.2m-76.0%

How much money is Quince Therapeutics, Inc. making?

Current yearPrevious yearGrowGrow %
Making money-$14.2m-$7.8m-$6.3m-44.8%
Net Profit Margin-9,596.2%0.0%--

How much money comes from the company's main activities?

2.3. Financial Health of Quince Therapeutics, Inc. (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  

3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Quince Therapeutics, Inc.?

Welcome investor! Quince Therapeutics, Inc.'s management wants to use your money to grow the business. In return you get a share of Quince Therapeutics, Inc..

First you should know what it really means to hold a share of Quince Therapeutics, Inc.. And how you can make/lose money.

Speculation

The Price per Share of Quince Therapeutics, Inc. is $1.01. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Quince Therapeutics, Inc..
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Quince Therapeutics, Inc., you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.70. Based on the TTM, the Book Value Change Per Share is $-0.32 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.09 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Quince Therapeutics, Inc..

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.29-28.5%-0.33-32.5%-0.18-18.0%-0.35-35.1%-0.32-31.8%
Usd Book Value Change Per Share-0.34-33.8%-0.32-31.4%-0.09-8.9%-0.10-9.8%0.032.8%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.34-33.8%-0.32-31.4%-0.09-8.9%-0.10-9.8%0.032.8%
Usd Price Per Share1.87-1.11-1.31-19.15-20.27-
Price to Earnings Ratio-1.62--1.12--2.06--10.60--13.57-
Price-to-Total Gains Ratio-5.47--6.84--3.94--55.98--62.42-
Price to Book Ratio2.68-1.19-0.65-5.47-6.10-
Price-to-Total Gains Ratio-5.47--6.84--3.94--55.98--62.42-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.01
Number of shares990
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.32-0.10
Usd Total Gains Per Share-0.32-0.10
Gains per Quarter (990 shares)-314.19-97.59
Gains per Year (990 shares)-1,256.77-390.35
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-1257-12670-390-400
20-2514-25240-781-790
30-3770-37810-1171-1180
40-5027-50380-1562-1570
50-6284-62950-1952-1960
60-7541-75520-2342-2350
70-8797-88090-2733-2740
80-10054-100661-3123-3130
90-11311-113231-3514-3520
100-12568-125801-3904-3910

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.025.00.00.0%0.025.00.00.0%
Book Value Change Per Share0.04.00.00.0%2.010.00.016.7%3.017.00.015.0%5.020.00.020.0%5.020.00.020.0%
Dividend per Share0.00.04.00.0%1.00.011.08.3%1.00.019.05.0%1.00.024.04.0%1.00.024.04.0%
Total Gains per Share0.04.00.00.0%2.010.00.016.7%3.017.00.015.0%5.020.00.020.0%5.020.00.020.0%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Quince Therapeutics, Inc. compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.342-0.317-7%-0.090-74%-0.099-71%0.028-1326%
Book Value Per Share--0.6971.134-39%1.995-65%2.655-74%2.505-72%
Current Ratio--6.0517.223-16%30.237-80%14.982-60%16.665-64%
Debt To Asset Ratio--0.7370.642+15%0.144+412%0.204+261%0.232+217%
Debt To Equity Ratio--2.7971.908+47%0.264+958%0.486+475%0.397+605%
Dividend Per Share----0%-0%0.000-100%0.000-100%
Enterprise Value--37379242.00017463296.230+114%99352500.250-62%896051663.206-96%1025901456.179-96%
Eps---0.288-0.328+14%-0.181-37%-0.354+23%-0.321+11%
Ev To Ebitda Ratio---0.926-0.466-50%inf+inf%inf+inf%inf+inf%
Ev To Sales Ratio--55.624nannan%nannan%nannan%nannan%
Free Cash Flow Per Share---0.178-0.186+5%-0.107-40%-0.253+43%-0.237+34%
Free Cash Flow To Equity Per Share---0.178-0.213+20%-0.106-40%-0.113-36%-0.053-70%
Gross Profit Margin--1.1880.995+19%1.000+19%0.999+19%0.999+19%
Intrinsic Value_10Y_max--1.784--------
Intrinsic Value_10Y_min--1.184--------
Intrinsic Value_1Y_max---0.669--------
Intrinsic Value_1Y_min---0.658--------
Intrinsic Value_3Y_max---1.365--------
Intrinsic Value_3Y_min---1.316--------
Intrinsic Value_5Y_max---1.281--------
Intrinsic Value_5Y_min---1.245--------
Market Cap43709366.000-85%80927242.00048212296.230+68%56638250.250+43%828894463.206-90%877040459.685-91%
Net Profit Margin---74.155-95.962+29%--100%-19.192-74%-15.354-79%
Operating Margin---60.173-75.272+25%--100%-15.054-75%-12.044-80%
Operating Ratio--72.00060.868+18%-+100%12.174+491%9.739+639%
Pb Ratio1.450-85%2.6851.185+126%0.654+311%5.474-51%6.100-56%
Pe Ratio-0.877+46%-1.624-1.119-31%-2.063+27%-10.602+553%-13.569+736%
Price Per Share1.010-85%1.8701.114+68%1.309+43%19.153-90%20.266-91%
Price To Free Cash Flow Ratio-1.422+46%-2.633-1.518-42%-3.297+25%-15.105+474%-18.452+601%
Price To Total Gains Ratio-2.956+46%-5.473-6.843+25%-3.938-28%-55.985+923%-62.421+1040%
Quick Ratio--10.35412.551-18%47.840-78%22.865-55%25.677-60%
Return On Assets---0.109-0.107-2%-0.075-31%-0.107-1%-0.100-8%
Return On Equity---0.413-0.319-23%-0.090-78%-0.159-61%-0.139-66%
Total Gains Per Share---0.342-0.317-7%-0.090-74%-0.099-71%0.028-1326%
Usd Book Value--30146000.00049055750.000-39%86326000.000-65%114907300.000-74%108420880.000-72%
Usd Book Value Change Per Share---0.342-0.317-7%-0.090-74%-0.099-71%0.028-1326%
Usd Book Value Per Share--0.6971.134-39%1.995-65%2.655-74%2.505-72%
Usd Dividend Per Share----0%-0%0.000-100%0.000-100%
Usd Enterprise Value--37379242.00017463296.230+114%99352500.250-62%896051663.206-96%1025901456.179-96%
Usd Eps---0.288-0.328+14%-0.181-37%-0.354+23%-0.321+11%
Usd Free Cash Flow---7685000.000-8040250.000+5%-4613000.000-40%-10969700.000+43%-10267960.000+34%
Usd Free Cash Flow Per Share---0.178-0.186+5%-0.107-40%-0.253+43%-0.237+34%
Usd Free Cash Flow To Equity Per Share---0.178-0.213+20%-0.106-40%-0.113-36%-0.053-70%
Usd Market Cap43709366.000-85%80927242.00048212296.230+68%56638250.250+43%828894463.206-90%877040459.685-91%
Usd Price Per Share1.010-85%1.8701.114+68%1.309+43%19.153-90%20.266-91%
Usd Profit---12458000.000-14207000.000+14%-7846250.000-37%-15351500.000+23%-13899200.000+12%
Usd Revenue--168000.00051000.000+229%-+100%10200.000+1547%8160.000+1959%
Usd Total Gains Per Share---0.342-0.317-7%-0.090-74%-0.099-71%0.028-1326%
 EOD+3 -5MRQTTM+20 -17YOY+6 -315Y+12 -2710Y+12 -27

3.3 Fundamental Score

Let's check the fundamental score of Quince Therapeutics, Inc. based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.877
Price to Book Ratio (EOD)Between0-11.450
Net Profit Margin (MRQ)Greater than0-74.155
Operating Margin (MRQ)Greater than0-60.173
Quick Ratio (MRQ)Greater than110.354
Current Ratio (MRQ)Greater than16.051
Debt to Asset Ratio (MRQ)Less than10.737
Debt to Equity Ratio (MRQ)Less than12.797
Return on Equity (MRQ)Greater than0.15-0.413
Return on Assets (MRQ)Greater than0.05-0.109
Total3/10 (30.0%)

3.4 Technical Score

Let's check the technical score of Quince Therapeutics, Inc. based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose1.020
Total1/1 (100.0%)

4. In-depth Analysis

4.1 About Quince Therapeutics, Inc.

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.

Fundamental data was last updated by Penke on 2025-04-05 22:00:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is just able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Quince Therapeutics, Inc. earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Quince Therapeutics, Inc. to the Biotechnology industry mean.
  • A Net Profit Margin of -7,415.5% means that $-74.15 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Quince Therapeutics, Inc.:

  • The MRQ is -7,415.5%. The company is making a huge loss. -2
  • The TTM is -9,596.2%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-7,415.5%TTM-9,596.2%+2,180.8%
TTM-9,596.2%YOY--9,596.2%
TTM-9,596.2%5Y-1,919.2%-7,677.0%
5Y-1,919.2%10Y-1,535.4%-383.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-7,415.5%-100.3%-7,315.2%
TTM-9,596.2%-188.1%-9,408.1%
YOY--200.1%+200.1%
5Y-1,919.2%-393.6%-1,525.6%
10Y-1,535.4%-501.9%-1,033.5%
4.3.1.2. Return on Assets

Shows how efficient Quince Therapeutics, Inc. is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Quince Therapeutics, Inc. to the Biotechnology industry mean.
  • -10.9% Return on Assets means that Quince Therapeutics, Inc. generated $-0.11 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Quince Therapeutics, Inc.:

  • The MRQ is -10.9%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -10.7%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-10.9%TTM-10.7%-0.2%
TTM-10.7%YOY-7.5%-3.1%
TTM-10.7%5Y-10.7%+0.0%
5Y-10.7%10Y-10.0%-0.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-10.9%-12.5%+1.6%
TTM-10.7%-12.3%+1.6%
YOY-7.5%-12.5%+5.0%
5Y-10.7%-13.8%+3.1%
10Y-10.0%-15.7%+5.7%
4.3.1.3. Return on Equity

Shows how efficient Quince Therapeutics, Inc. is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Quince Therapeutics, Inc. to the Biotechnology industry mean.
  • -41.3% Return on Equity means Quince Therapeutics, Inc. generated $-0.41 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Quince Therapeutics, Inc.:

  • The MRQ is -41.3%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -31.9%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-41.3%TTM-31.9%-9.4%
TTM-31.9%YOY-9.0%-22.9%
TTM-31.9%5Y-15.9%-16.0%
5Y-15.9%10Y-13.9%-2.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-41.3%-16.1%-25.2%
TTM-31.9%-16.2%-15.7%
YOY-9.0%-16.1%+7.1%
5Y-15.9%-21.0%+5.1%
10Y-13.9%-22.2%+8.3%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Quince Therapeutics, Inc..

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Quince Therapeutics, Inc. is operating .

  • Measures how much profit Quince Therapeutics, Inc. makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Quince Therapeutics, Inc. to the Biotechnology industry mean.
  • An Operating Margin of -6,017.3% means the company generated $-60.17  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Quince Therapeutics, Inc.:

  • The MRQ is -6,017.3%. The company is operating very inefficient. -2
  • The TTM is -7,527.2%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-6,017.3%TTM-7,527.2%+1,510.0%
TTM-7,527.2%YOY--7,527.2%
TTM-7,527.2%5Y-1,505.4%-6,021.8%
5Y-1,505.4%10Y-1,204.4%-301.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-6,017.3%-193.7%-5,823.6%
TTM-7,527.2%-286.4%-7,240.8%
YOY--223.4%+223.4%
5Y-1,505.4%-393.8%-1,111.6%
10Y-1,204.4%-475.0%-729.4%
4.3.2.2. Operating Ratio

Measures how efficient Quince Therapeutics, Inc. is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 72.00 means that the operating costs are $72.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Quince Therapeutics, Inc.:

  • The MRQ is 72.000. The company is inefficient in keeping operating costs low. -1
  • The TTM is 60.868. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ72.000TTM60.868+11.132
TTM60.868YOY-+60.868
TTM60.8685Y12.174+48.694
5Y12.17410Y9.739+2.435
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ72.0002.208+69.792
TTM60.8683.152+57.716
YOY-3.121-3.121
5Y12.1745.168+7.006
10Y9.7396.512+3.227
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Quince Therapeutics, Inc..

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Quince Therapeutics, Inc. is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 6.05 means the company has $6.05 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Quince Therapeutics, Inc.:

  • The MRQ is 6.051. The company is very able to pay all its short-term debts. +2
  • The TTM is 7.223. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ6.051TTM7.223-1.172
TTM7.223YOY30.237-23.015
TTM7.2235Y14.982-7.760
5Y14.98210Y16.665-1.683
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.0513.726+2.325
TTM7.2233.930+3.293
YOY30.2374.316+25.921
5Y14.9825.777+9.205
10Y16.6656.144+10.521
4.4.3.2. Quick Ratio

Measures if Quince Therapeutics, Inc. is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Quince Therapeutics, Inc. to the Biotechnology industry mean.
  • A Quick Ratio of 10.35 means the company can pay off $10.35 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Quince Therapeutics, Inc.:

  • The MRQ is 10.354. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 12.551. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ10.354TTM12.551-2.197
TTM12.551YOY47.840-35.289
TTM12.5515Y22.865-10.314
5Y22.86510Y25.677-2.812
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ10.3542.944+7.410
TTM12.5513.417+9.134
YOY47.8404.212+43.628
5Y22.8655.714+17.151
10Y25.6776.434+19.243
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Quince Therapeutics, Inc..

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Quince Therapeutics, Inc. assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Quince Therapeutics, Inc. to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.74 means that Quince Therapeutics, Inc. assets are financed with 73.7% credit (debt) and the remaining percentage (100% - 73.7%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Quince Therapeutics, Inc.:

  • The MRQ is 0.737. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.642. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.737TTM0.642+0.095
TTM0.642YOY0.144+0.498
TTM0.6425Y0.204+0.438
5Y0.20410Y0.232-0.028
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7370.342+0.395
TTM0.6420.343+0.299
YOY0.1440.330-0.186
5Y0.2040.362-0.158
10Y0.2320.387-0.155
4.5.4.2. Debt to Equity Ratio

Measures if Quince Therapeutics, Inc. is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Quince Therapeutics, Inc. to the Biotechnology industry mean.
  • A Debt to Equity ratio of 279.7% means that company has $2.80 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Quince Therapeutics, Inc.:

  • The MRQ is 2.797. The company is unable to pay all its debts with equity. -1
  • The TTM is 1.908. The company is just able to pay all its debts with equity.
Trends
Current periodCompared to+/- 
MRQ2.797TTM1.908+0.890
TTM1.908YOY0.264+1.643
TTM1.9085Y0.486+1.422
5Y0.48610Y0.397+0.089
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.7970.402+2.395
TTM1.9080.421+1.487
YOY0.2640.396-0.132
5Y0.4860.446+0.040
10Y0.3970.486-0.089
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Quince Therapeutics, Inc. generates.

  • Above 15 is considered overpriced but always compare Quince Therapeutics, Inc. to the Biotechnology industry mean.
  • A PE ratio of -1.62 means the investor is paying $-1.62 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Quince Therapeutics, Inc.:

  • The EOD is -0.877. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.624. Based on the earnings, the company is expensive. -2
  • The TTM is -1.119. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.877MRQ-1.624+0.747
MRQ-1.624TTM-1.119-0.505
TTM-1.119YOY-2.063+0.944
TTM-1.1195Y-10.602+9.484
5Y-10.60210Y-13.569+2.967
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.877-1.758+0.881
MRQ-1.624-2.592+0.968
TTM-1.119-3.216+2.097
YOY-2.063-3.278+1.215
5Y-10.602-6.457-4.145
10Y-13.569-7.176-6.393
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Quince Therapeutics, Inc.:

  • The EOD is -1.422. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -2.633. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -1.518. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.422MRQ-2.633+1.211
MRQ-2.633TTM-1.518-1.114
TTM-1.518YOY-3.297+1.778
TTM-1.5185Y-15.105+13.587
5Y-15.10510Y-18.452+3.346
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.422-2.331+0.909
MRQ-2.633-3.585+0.952
TTM-1.518-4.034+2.516
YOY-3.297-4.487+1.190
5Y-15.105-8.803-6.302
10Y-18.452-9.972-8.480
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Quince Therapeutics, Inc. is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 2.68 means the investor is paying $2.68 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Quince Therapeutics, Inc.:

  • The EOD is 1.450. Based on the equity, the company is underpriced. +1
  • The MRQ is 2.685. Based on the equity, the company is underpriced. +1
  • The TTM is 1.185. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.450MRQ2.685-1.235
MRQ2.685TTM1.185+1.499
TTM1.185YOY0.654+0.532
TTM1.1855Y5.474-4.288
5Y5.47410Y6.100-0.626
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.4501.585-0.135
MRQ2.6852.265+0.420
TTM1.1852.441-1.256
YOY0.6542.512-1.858
5Y5.4743.773+1.701
10Y6.1004.294+1.806
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Quince Therapeutics, Inc..

4.8.1. Institutions holding Quince Therapeutics, Inc.

Institutions are holding 25.24% of the shares of Quince Therapeutics, Inc..

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-12-31Vanguard Group Inc2.891601272340726926.0594
2024-12-31EPIQ Capital Group, LLC1.87440.4023824782-1160-0.1404
2024-12-31Renaissance Technologies Corp1.18870.00155230504740.0907
2024-12-31BlackRock Inc1.017504477338937524.9401
2024-12-31Geode Capital Management, LLC0.85440.00013759323680710.8535
2024-12-31HighTower Advisors, LLC0.77630.000934157000
2024-12-31Shay Capital LLC0.62910.078527679910461660.7586
2024-12-31Alphabet Inc0.42980.020618912200
2024-12-31ADAR1 Capital Management LLC0.32490.053414295800
2024-12-31State Street Corp0.2839012491168300120.6479
2024-12-31Mariner Wealth Advisors LLC0.27830.000412246100
2024-12-31Bridgeway Capital Management, LLC0.20980.00399231738224.3189
2024-12-31Scharf Investments0.20690.005191061910610
2024-12-31Morgan Stanley - Brokerage Accounts0.174307670168179800.0352
2024-12-31Northern Trust Corp0.11480505241650148.4995
2024-12-31Two Sigma Investments LLC0.0690.000130341303410
2024-12-31Virtu Financial LLC0.06640.002929204292040
2024-12-31Anfield Capital Management, LLC0.06060.018126656266560
2024-12-31HRT FINANCIAL LLC0.0460.000220232202320
2024-12-31Kestra Advisory Services, LLC0.03490.000215359153590
Total 11.53160.58825074053+672459+13.3%

4.9.2. Funds holding Quince Therapeutics, Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-02-28Vanguard Total Stock Mkt Idx Inv1.95460.0001860059121001.427
2025-02-28Vanguard Institutional Extnd Mkt Idx Tr0.95050.000541822000
2025-01-31Fidelity Extended Market Index0.43010.0007189241-2874-1.496
2025-02-28iShares Micro-Cap ETF0.19480.0148572200
2025-01-31Fidelity Total Market Index0.14180.000162399-268-0.4277
2024-12-31Bridgeway Ultra-Small Company Market0.13370.0615882238226.9491
2025-01-31Fidelity Series Total Market Index0.10260.00014513500
2025-01-31Spartan Extended Market Index Pool E0.07850.00083453228749.0783
2024-12-31NT Ext Equity Mkt Idx Fd - L0.07760.0008341311650193.5961
2024-12-31Northern Trust Extended Eq Market Idx0.07760.0008341311650193.5961
2024-12-31Bridgeway Ultra-Small Company0.07610.06723349500
2024-12-31Extended Equity Market Fund K0.06930.000430508-420-1.358
2025-01-31Fidelity Nasdaq Composite Index0.05760.00022534000
2025-01-31Spartan Total Market Index Pool E0.04330.0001190722681.4252
2024-12-31NT Ext Equity Mkt Idx Fd - NL0.03280.00041445400
2024-12-31NT Ext Equity Mkt Idx Fd - DC - NL - T20.0260.000411456-189-1.623
2024-12-31NT Ext Eq Mkt Indx Fd DC Lend T40.01850.0008813381330
2024-12-31NT Ext Eq Mkt Indx Fd DC Lend T30.01850.0008813381330
2025-02-28State St US Extended Mkt Indx NL Cl C0.01820.0006800000
2025-01-311290 VT Micro Cap K0.01670.0071735700
Total 4.51880.15691988340+64581+3.2%

5.3. Insider Transactions

Insiders are holding 13.744% of the shares of Quince Therapeutics, Inc..

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-08-29Dirk ThyeBUY775000.69
2024-08-21Brendan HannahBUY308450.63
2024-08-20Charles S RyanBUY483870.65
2024-08-19Brendan HannahBUY21550.58
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2024-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets114,478
Total Liabilities84,332
Total Stockholder Equity30,146
 As reported
Total Liabilities 84,332
Total Stockholder Equity+ 30,146
Total Assets = 114,478

Assets

Total Assets114,478
Total Current Assets44,036
Long-term Assets70,442
Total Current Assets
Cash And Cash Equivalents 6,212
Short-term Investments 34,572
Other Current Assets 3,252
Total Current Assets  (as reported)44,036
Total Current Assets  (calculated)44,036
+/-0
Long-term Assets
Property Plant Equipment 813
Long Term Investments 78
Intangible Assets 60,045
Long-term Assets Other 9,584
Long-term Assets  (as reported)70,442
Long-term Assets  (calculated)70,520
+/- 78

Liabilities & Shareholders' Equity

Total Current Liabilities7,278
Long-term Liabilities77,054
Total Stockholder Equity30,146
Total Current Liabilities
Short-term Debt 96
Accounts payable 2,903
Other Current Liabilities 4,279
Total Current Liabilities  (as reported)7,278
Total Current Liabilities  (calculated)7,278
+/-0
Long-term Liabilities
Long term Debt 14,321
Capital Lease Obligations 490
Long-term Liabilities Other 57,376
Long-term Liabilities  (as reported)77,054
Long-term Liabilities  (calculated)72,187
+/- 4,867
Total Stockholder Equity
Common Stock44
Retained Earnings -376,472
Accumulated Other Comprehensive Income -35
Other Stockholders Equity 406,609
Total Stockholder Equity (as reported)30,146
Total Stockholder Equity (calculated)30,146
+/-0
Other
Capital Stock44
Cash and Short Term Investments 40,784
Common Stock Shares Outstanding 43,262
Liabilities and Stockholders Equity 114,478
Net Debt 8,599
Net Invested Capital 44,467
Net Working Capital 36,758
Property Plant and Equipment Gross 1,452
Short Long Term Debt Total 14,811



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-31
> Total Assets 
0
0
0
72,878
70,596
143,242
133,414
124,370
231,205
219,210
204,664
189,466
174,522
161,390
147,416
133,228
116,130
117,863
109,777
103,910
93,318
88,836
85,386
167,900
159,292
134,829
126,519
114,478
114,478126,519134,829159,292167,90085,38688,83693,318103,910109,777117,863116,130133,228147,416161,390174,522189,466204,664219,210231,205124,370133,414143,24270,59672,878000
   > Total Current Assets 
0
0
0
72,585
63,790
133,643
124,369
106,056
168,588
151,608
142,974
137,862
149,885
135,843
119,427
111,673
96,353
99,370
98,276
93,748
92,491
88,548
85,173
77,440
70,439
63,438
51,718
44,036
44,03651,71863,43870,43977,44085,17388,54892,49193,74898,27699,37096,353111,673119,427135,843149,885137,862142,974151,608168,588106,056124,369133,64363,79072,585000
       Cash And Cash Equivalents 
0
0
0
24,873
20,634
44,314
44,740
51,214
85,606
66,156
64,246
66,841
85,315
74,049
62,207
69,724
67,564
46,928
31,809
44,579
46,714
22,650
21,632
20,752
21,813
7,890
2,675
6,212
6,2122,6757,89021,81320,75221,63222,65046,71444,57931,80946,92867,56469,72462,20774,04985,31566,84164,24666,15685,60651,21444,74044,31420,63424,873000
       Short-term Investments 
0
0
0
46,844
38,410
83,974
75,730
48,650
76,810
78,348
73,548
66,979
61,720
55,901
52,205
37,078
23,960
47,736
62,534
45,602
43,489
64,915
61,593
54,307
46,010
51,555
45,172
34,572
34,57245,17251,55546,01054,30761,59364,91543,48945,60262,53447,73623,96037,07852,20555,90161,72066,97973,54878,34876,81048,65075,73083,97438,41046,844000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,128
1,558
2,063
1,042
1,003
472
0
500
0
993
964
995
0
0995964993050004721,0031,0422,0631,5581,128000000000000000
       Other Current Assets 
0
0
0
68
387
446
512
688
954
883
629
694
557
438
495
1,495
2,045
387
336
276
179
143
92
81
2,616
3,993
2,876
3,252
3,2522,8763,9932,61681921431792763363872,0451,49549543855769462988395468851244638768000
   > Long-term Assets 
0
0
0
293
6,806
9,599
9,045
18,314
62,617
67,602
61,690
51,604
24,637
25,547
27,989
21,555
19,777
18,493
11,501
10,162
827
288
213
90,460
88,853
71,391
74,801
70,442
70,44274,80171,39188,85390,46021328882710,16211,50118,49319,77721,55527,98925,54724,63751,60461,69067,60262,61718,3149,0459,5996,806293000
       Property Plant Equipment 
0
0
0
283
1,129
1,351
1,441
1,334
1,261
1,251
1,348
1,101
878
1,886
1,655
1,428
573
692
583
684
177
116
53
619
810
800
767
813
813767800810619531161776845836925731,4281,6551,8868781,1011,3481,2511,2611,3341,4411,3511,129283000
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
825
0
0
0
0
0
17,625
17,245
0
0
0
00017,24517,6250000082500000000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
23,516
26,141
19,933
19,175
11,029
5,001
3,578
545
78
78
78
78
78
78
78
787878787878785453,5785,00111,02919,17519,93326,14123,5160000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5,900
5,900
5,900
0
0
0
63,672
62,253
61,793
64,528
60,045
60,04564,52861,79362,25363,6720005,9005,9005,90000000000000000000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
145
193
194
29
47
17
0
0
94
0
0
0
0
0
0
00000094001747291941931450000000000000
> Total Liabilities 
0
0
0
1,457
108,623
7,025
6,127
8,892
13,164
13,743
16,653
17,204
18,038
19,310
14,764
14,642
9,750
6,331
5,246
3,317
3,115
1,952
2,253
82,816
85,115
87,861
81,587
84,332
84,33281,58787,86185,11582,8162,2531,9523,1153,3175,2466,3319,75014,64214,76419,31018,03817,20416,65313,74313,1648,8926,1277,025108,6231,457000
   > Total Current Liabilities 
0
0
0
1,457
4,010
7,025
6,127
8,892
13,107
13,693
16,409
16,996
17,867
18,537
14,154
14,222
9,710
5,950
4,945
3,069
3,115
1,952
2,253
9,572
9,838
10,321
5,425
7,278
7,2785,42510,3219,8389,5722,2531,9523,1153,0694,9455,9509,71014,22214,15418,53717,86716,99616,40913,69313,1078,8926,1277,0254,0101,457000
       Short-term Debt 
0
0
0
0
340
0
0
0
0
0
0
0
0
0
0
741
299
391
367
453
269
147
61
0
93
94
101
96
96101949306114726945336739129974100000000003400000
       Accounts payable 
0
0
0
495
1,946
5,116
2,295
3,075
4,954
5,091
4,309
3,555
2,845
7,193
2,880
4,911
3,731
1,867
1,181
570
1,651
353
409
2,033
2,070
2,405
1,622
2,903
2,9031,6222,4052,0702,0334093531,6515701,1811,8673,7314,9112,8807,1932,8453,5554,3095,0914,9543,0752,2955,1161,946495000
       Other Current Liabilities 
0
0
0
962
21
1,909
3,832
5,817
8,153
8,602
12,100
13,441
15,022
11,344
11,274
180
5,680
3,692
3,397
2,046
1,195
83
-258
4,360
7,675
7,822
3,702
4,279
4,2793,7027,8227,6754,360-258831,1952,0463,3973,6925,68018011,27411,34415,02213,44112,1008,6028,1535,8173,8321,90921962000
   > Long-term Liabilities 
0
0
0
495
104,613
5,116
2,295
3,075
57
50
244
208
171
773
610
420
40
381
301
248
1,651
0
0
73,244
75,277
77,540
76,162
77,054
77,05476,16277,54075,27773,244001,6512483013814042061077317120824450573,0752,2955,116104,613495000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
248
248
248
0
0
0
0
0
0
0
0
0000000024824824800000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
248
0
0
0
0
0
0
0
0
000000002480000000000000000000
> Total Stockholder Equity
0
0
0
71,421
-38,027
136,217
127,287
115,478
218,041
205,467
188,011
172,262
156,484
142,080
132,652
118,586
106,380
111,532
104,531
100,593
90,203
86,884
83,133
85,084
74,177
46,968
44,932
30,146
30,14644,93246,96874,17785,08483,13386,88490,203100,593104,531111,532106,380118,586132,652142,080156,484172,262188,011205,467218,041115,478127,287136,217-38,02771,421000
   Common Stock
0
0
0
22
4
27
27
27
29
29
29
29
29
30
30
30
30
36
36
36
36
36
36
0
43
43
43
44
444343430363636363636303030302929292929272727422000
   Retained Earnings Total Equity000000-305,399-300,513-288,2590000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
-49
-23
80
96
60
-37
711
513
313
189
117
71
-79
-506
-466
-253
-289
38
257
516
0
1,825
1,087
3,419
-35
-353,4191,0871,825051625738-289-253-466-506-7971117189313513711-37609680-23-49000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
389,105
390,642
391,990
0
0
0
0
0
0
000000391,990390,642389,1050000000000000000000
   Treasury Stock0000000000000000000000000000
   Other Stockholders Equity 
0
0
0
104,273
-16,680
40,436
51,176
185,196
73,825
309,320
313,568
318,574
326,006
333,427
345,751
355,234
365,096
386,766
387,473
389,105
390,642
391,990
393,331
0
403,102
404,360
405,484
406,609
406,609405,484404,360403,1020393,331391,990390,642389,105387,473386,766365,096355,234345,751333,427326,006318,574313,568309,32073,825185,19651,17640,436-16,680104,273000



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue0
Cost of Revenue-0
Gross Profit00
 
Operating Income (+$)
Gross Profit0
Operating Expense-57,285
Operating Income-57,285-57,285
 
Operating Expense (+$)
Research Development18,590
Selling General Administrative17,580
Selling And Marketing Expenses0
Operating Expense57,28536,170
 
Net Interest Income (+$)
Interest Income2,929
Interest Expense-0
Other Finance Cost-0
Net Interest Income2,929
 
Pretax Income (+$)
Operating Income-57,285
Net Interest Income2,929
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-56,741-57,829
EBIT - interestExpense = 0
-56,915
-56,828
Interest Expense0
Earnings Before Interest and Taxes (EBIT)0-56,741
Earnings Before Interest and Taxes (EBITDA)-57,285
 
After tax Income (+$)
Income Before Tax-56,741
Tax Provision-87
Net Income From Continuing Ops-56,828-56,828
Net Income-56,828
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net544-2,929
 

Technical Analysis of Quince Therapeutics, Inc.
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Quince Therapeutics, Inc.. The general trend of Quince Therapeutics, Inc. is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Quince Therapeutics, Inc.'s overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Quince Therapeutics, Inc. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Quince Therapeutics, Inc..

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 1.28 < 1.3 < 1.3.

The bearish price targets are: 1.01 > 0.97 > 0.9195.

Know someone who trades $QNCX? Share this with them.👇

Quince Therapeutics, Inc. Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Quince Therapeutics, Inc.. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Quince Therapeutics, Inc. Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Quince Therapeutics, Inc..

Quince Therapeutics, Inc. Daily Moving Average Convergence/Divergence (MACD) ChartQuince Therapeutics, Inc. Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Quince Therapeutics, Inc.. The current adx is .

Quince Therapeutics, Inc. Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Quince Therapeutics, Inc..

Quince Therapeutics, Inc. Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Quince Therapeutics, Inc..

Quince Therapeutics, Inc. Daily Relative Strength Index (RSI) ChartQuince Therapeutics, Inc. Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Quince Therapeutics, Inc..

Quince Therapeutics, Inc. Daily Stochastic Oscillator ChartQuince Therapeutics, Inc. Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Quince Therapeutics, Inc..

Quince Therapeutics, Inc. Daily Commodity Channel Index (CCI) ChartQuince Therapeutics, Inc. Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Quince Therapeutics, Inc..

Quince Therapeutics, Inc. Daily Chande Momentum Oscillator (CMO) ChartQuince Therapeutics, Inc. Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Quince Therapeutics, Inc..

Quince Therapeutics, Inc. Daily Williams %R ChartQuince Therapeutics, Inc. Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Quince Therapeutics, Inc..

Quince Therapeutics, Inc. Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Quince Therapeutics, Inc..

Quince Therapeutics, Inc. Daily Average True Range (ATR) ChartQuince Therapeutics, Inc. Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Quince Therapeutics, Inc..

Quince Therapeutics, Inc. Daily On-Balance Volume (OBV) ChartQuince Therapeutics, Inc. Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Quince Therapeutics, Inc..

Quince Therapeutics, Inc. Daily Money Flow Index (MFI) ChartQuince Therapeutics, Inc. Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Quince Therapeutics, Inc..

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-11-20STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-11-21WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-22SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-25MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-11-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-03CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-12-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-05CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-12-06STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-12-09SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-12-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-16CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-12-17CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-12-19SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-12-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-27CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-12-30CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-12-31CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-01-06SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-01-07STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-08CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-01-14CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-01-15STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-16SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-01-21DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-01-27CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-01-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-01-29STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-30STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-31STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-03DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-02-04DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-05MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-02-06STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-02-07MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-02-10WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-02-13STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-14STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-18STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-19DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-02-20DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-02-21STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-24MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-02-25MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-02-28SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-03DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-03-05WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-03-06STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-03-10CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-11SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-03-12STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-19STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-24MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-03-25STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-26MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-28STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-31MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-04-01WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-02STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-03STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-07STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-08STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-04-10STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-11MFI SHORT ENTRY LONG CLOSE20 crossover to downside

6.3. Candlestick Patterns

Quince Therapeutics, Inc. Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Quince Therapeutics, Inc. based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose1.020
Total1/1 (100.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Quince Therapeutics, Inc. with someone you think should read this too:
  • Are you bullish or bearish on Quince Therapeutics, Inc.? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Quince Therapeutics, Inc.? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Quince Therapeutics, Inc.

I send you an email if I find something interesting about Quince Therapeutics, Inc..


Comments

How you think about this?

Leave a comment

Stay informed about Quince Therapeutics, Inc..

Receive notifications about Quince Therapeutics, Inc. in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.